Clinical trial

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

NCT00431873

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-01-01

PhasePHASE2

Study timeline

Study start (unknown)2007-01-01Date precision: month

Registry last updated2015-07-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lymphocytic Leukemia, Chronicunresolved

Interventions

MGCD0103DRUG

Sponsors & collaborators

Mirati Therapeutics Inc.lead sponsor

Mapped research locations

New YorkNew York, United States1 HoustonTexas, United States1 TorontoOntario, Canada1 ClevelandOhio, United States1 MontrealQuebec, Canada1 Kansas CityMissouri, United States1 OttawaOntario, Canada1 HamiltonOntario, Canada1 QuébecQuebec, Canada1 CantonOhio, United States1 HalifaxNova Scotia, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00431873 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.